Amgen (AMG) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMG Analyst Ratings

Moderate Buy

8 Buy

11 Hold

1 Sell

Based on 20 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMG Stock 12 Month Forecast

Average Price Target

CHF257.57

▲(13.79% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is CHF257.57 with a high forecast of CHF322.58 and a low forecast of CHF216.65. The average price target represents a 13.79% change from the last price of CHF226.36.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"215":"CHF215","242":"CHF242","269":"CHF269","296":"CHF296","323":"CHF323"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":322.5827025,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF322.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":257.57233169,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF257.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":216.648136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF216.65</span>\n  </div></div>","useHTML":true}}],"tickPositions":[215,242,269,296,323],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,226.357,233.75897711538462,241.16095423076922,248.56293134615385,255.96490846153847,263.3668855769231,270.76886269230766,278.1708398076923,285.5728169230769,292.97479403846154,300.3767711538461,307.77874826923073,315.18072538461536,{"y":322.5827025,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,226.357,228.75817936076922,231.15935872153847,233.5605380823077,235.96171744307694,238.36289680384616,240.76407616461537,243.16525552538462,245.56643488615384,247.96761424692306,250.3687936076923,252.76997296846153,255.17115232923078,{"y":257.57233169,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,226.357,225.61016430769232,224.8633286153846,224.11649292307692,223.36965723076923,222.62282153846152,221.87598584615384,221.12915015384615,220.38231446153847,219.63547876923076,218.88864307692307,218.1418073846154,217.39497169230768,{"y":216.648136,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":226.357,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF322.58

Average Price TargetCHF257.57

Lowest Price TargetCHF216.65

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Amsellem

Piper Sandler

CHF270.63

Buy

19.56%

Upside

Reiterated

10/17/25

Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)

Mohit Bansal

Wells Fargo

CHF221.57

Hold

-2.12%

Downside

Reiterated

10/16/25

Wells Fargo Reaffirms Their Hold Rating on Amgen (AMGN)

David Risinger

Leerink Partners

―

Hold

―

Reiterated

10/14/25

Analysts Conflicted on These Healthcare Names: Abbott Laboratories (NYSE: ABT), Amgen (NASDAQ: AMGN) and Pharvaris (NASDAQ: PHVS)

Geoff Meacham

Citi

CHF249.27

Hold

10.12%

Upside

Reiterated

10/10/25

Citi Keeps Their Hold Rating on Amgen (AMGN)

Christopher Raymond

Raymond James

―

Hold

―

Reiterated

10/10/25

Amgen (AMGN) Receives a Hold from Raymond James

Luca Issi

RBC Capital

―

Buy

―

Reiterated

10/08/25

RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)

Jay Olson

Oppenheimer

CHF300.7

Buy

32.84%

Upside

Reiterated

10/03/25

Oppenheimer Sticks to Its Buy Rating for Amgen (AMGN)

Yaron Werber

TD Cowen

CHF307.83

Buy

35.99%

Upside

Reiterated

10/02/25

TD Cowen Remains a Buy on Amgen (AMGN)

Veda Pharmyne

TR | OpenAI - 4o

CHF242.15→CHF245.31

Buy

8.37%

Upside

Upgraded

10/01/25

AI Generated ArticleAI Generated Article

Courtney Breen

Bernstein

CHF265.09

Buy

17.11%

Upside

Reiterated

09/30/25

Bernstein Reaffirms Their Buy Rating on Amgen (AMGN)

Tim Anderson

Bank of America Securities

CHF215.24

Sell

-4.91%

Downside

Reiterated

09/26/25

Bank of America Securities Sticks to Their Sell Rating for Amgen (AMGN)

Chris Schott

J.P. Morgan

CHF237.4

Hold

4.88%

Upside

Reiterated

09/16/25

J.P. Morgan Reaffirms Their Hold Rating on Amgen (AMGN)

Vamil Divan

Guggenheim

CHF227.9

Hold

0.68%

Upside

Reiterated

09/05/25

Amgen (AMGN) Gets a Hold from Guggenheim

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/03/25

Amgen's Strategic Focus and Portfolio Strength Justify Buy Rating Despite Bemarituzumab Challenges

Salim Syed

Mizuho Securities

CHF221.57

Hold

-2.12%

Downside

Reiterated

08/18/25

Mizuho Securities Keeps Their Hold Rating on Amgen (AMGN)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Amsellem

Piper Sandler

CHF270.63

Buy

19.56%

Upside

Reiterated

10/17/25

Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)

Mohit Bansal

Wells Fargo

CHF221.57

Hold

-2.12%

Downside

Reiterated

10/16/25

Wells Fargo Reaffirms Their Hold Rating on Amgen (AMGN)

David Risinger

Leerink Partners

―

Hold

―

Reiterated

10/14/25

Analysts Conflicted on These Healthcare Names: Abbott Laboratories (NYSE: ABT), Amgen (NASDAQ: AMGN) and Pharvaris (NASDAQ: PHVS)

Geoff Meacham

Citi

CHF249.27

Hold

10.12%

Upside

Reiterated

10/10/25

Citi Keeps Their Hold Rating on Amgen (AMGN)

Christopher Raymond

Raymond James

―

Hold

―

Reiterated

10/10/25

Amgen (AMGN) Receives a Hold from Raymond James

Luca Issi

RBC Capital

―

Buy

―

Reiterated

10/08/25

RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)

Jay Olson

Oppenheimer

CHF300.7

Buy

32.84%

Upside

Reiterated

10/03/25

Oppenheimer Sticks to Its Buy Rating for Amgen (AMGN)

Yaron Werber

TD Cowen

CHF307.83

Buy

35.99%

Upside

Reiterated

10/02/25

TD Cowen Remains a Buy on Amgen (AMGN)

Veda Pharmyne

TR | OpenAI - 4o

CHF242.15→CHF245.31

Buy

8.37%

Upside

Upgraded

10/01/25

AI Generated ArticleAI Generated Article

Courtney Breen

Bernstein

CHF265.09

Buy

17.11%

Upside

Reiterated

09/30/25

Bernstein Reaffirms Their Buy Rating on Amgen (AMGN)

Tim Anderson

Bank of America Securities

CHF215.24

Sell

-4.91%

Downside

Reiterated

09/26/25

Bank of America Securities Sticks to Their Sell Rating for Amgen (AMGN)

Chris Schott

J.P. Morgan

CHF237.4

Hold

4.88%

Upside

Reiterated

09/16/25

J.P. Morgan Reaffirms Their Hold Rating on Amgen (AMGN)

Vamil Divan

Guggenheim

CHF227.9

Hold

0.68%

Upside

Reiterated

09/05/25

Amgen (AMGN) Gets a Hold from Guggenheim

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/03/25

Amgen's Strategic Focus and Portfolio Strength Justify Buy Rating Despite Bemarituzumab Challenges

Salim Syed

Mizuho Securities

CHF221.57

Hold

-2.12%

Downside

Reiterated

08/18/25

Mizuho Securities Keeps Their Hold Rating on Amgen (AMGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

1 Month

xxx

Success Rate

21/41 ratings generated profit

Average Return

+0.69%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 51.22% of your transactions generating a profit, with an average return of +0.69% per trade.

3 Months

xxx

Success Rate

16/26 ratings generated profit

Average Return

+3.00%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +3.00% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

31/41 ratings generated profit

Average Return

+11.52%

reiterated a buy rating 18 days ago

Copying Yaron Werber's trades and holding each position for 1 Year would result in 73.17% of your transactions generating a profit, with an average return of +11.52% per trade.

2 Years

xxx

Success Rate

43/54 ratings generated profit

Average Return

+16.98%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 79.63% of your transactions generating a profit, with an average return of +16.98% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMG Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMG has received 22 Buy Ratings, 23 Hold Ratings, and 2 Sell Ratings. AMG average Analyst price target in the past 3 months is 257.57.

Each month's total comprises the sum of three months' worth of ratings.

AMG Financial Forecast

AMG Earnings Forecast

Next quarter’s earnings estimate for AMG is CHF4.01 with a range of CHF3.49 to CHF4.35. The previous quarter’s EPS was CHF4.79. AMG beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year AMG has Preformed in-line its overall industry.

AMG Sales Forecast

Next quarter’s sales forecast for AMG is CHF7.16B with a range of CHF6.99B to CHF7.33B. The previous quarter’s sales results were CHF7.30B. AMG beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year AMG has Preformed in-line its overall industry.

AMG Stock Forecast FAQ

What is CH:AMG’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen Inc’s 12-month average price target is 257.57.

What is CH:AMG’s upside potential, based on the analysts’ average price target?

Amgen Inc has 13.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Amgen Inc a Buy, Sell or Hold?

Amgen Inc has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 11 hold ratings and 1 sell ratings.

What is Amgen Inc’s share price target?

The average share price target for Amgen Inc is 257.57. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF322.58 ,and the lowest forecast is CHF216.65. The average share price target represents 13.79% Increase from the current price of CHF226.36.

What do analysts say about Amgen Inc?

Amgen Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of Amgen Inc?

To buy shares of CH:AMG, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Amgen (AMG) Stock Forecast & Price Target

AMG Analyst Ratings

AMG Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

AMG Analyst Recommendation Trends

AMG Financial Forecast

AMG Earnings Forecast

AMG Sales Forecast

AMG Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts